MXPA06005639A - Adyuvante antimicrobiano. - Google Patents

Adyuvante antimicrobiano.

Info

Publication number
MXPA06005639A
MXPA06005639A MXPA06005639A MXPA06005639A MXPA06005639A MX PA06005639 A MXPA06005639 A MX PA06005639A MX PA06005639 A MXPA06005639 A MX PA06005639A MX PA06005639 A MXPA06005639 A MX PA06005639A MX PA06005639 A MXPA06005639 A MX PA06005639A
Authority
MX
Mexico
Prior art keywords
adjuvant
vaccine
azalide
antimicrobial agent
vaccine adjuvants
Prior art date
Application number
MXPA06005639A
Other languages
English (en)
Inventor
Randy Dean Leyh
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06005639A publication Critical patent/MXPA06005639A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion describe una composicion de adyuvantes que comprende un agente antimicrobiano, en particular una azalida, en la que el agente antimicrobiano actua como un adyuvante. Mas particularmente, la composicion de adyuvantes es un adyuvante de vacunas. La invencion ademas describe una vacuna que comprende varios componentes comprendiendo (a) al menos un antigeno y (b) al menos un agente antimicrobiano, en particular una azalida, en la que la azalida actua como un adyuvante. Una composicion de adyuvantes o vacuna de la presente invencion es util en la prevencion y tratamiento de enfermedades producidas por un agente patogeno, una celula cancerosa, o un alergeno.
MXPA06005639A 2003-11-21 2004-11-08 Adyuvante antimicrobiano. MXPA06005639A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52409703P 2003-11-21 2003-11-21
PCT/IB2004/003694 WO2005049081A1 (en) 2003-11-21 2004-11-08 The use of anti biotics as vaccine adjuvants

Publications (1)

Publication Number Publication Date
MXPA06005639A true MXPA06005639A (es) 2006-08-17

Family

ID=34619630

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06005639A MXPA06005639A (es) 2003-11-21 2004-11-08 Adyuvante antimicrobiano.

Country Status (16)

Country Link
US (1) US20070141086A1 (es)
EP (1) EP1689434A1 (es)
JP (1) JP2007512312A (es)
KR (1) KR100785601B1 (es)
CN (1) CN1882360A (es)
AR (1) AR047728A1 (es)
AU (1) AU2004290982B2 (es)
BR (1) BRPI0416205A (es)
CA (1) CA2546195A1 (es)
IL (1) IL175373A0 (es)
MX (1) MXPA06005639A (es)
NO (1) NO20062918L (es)
RU (1) RU2322241C2 (es)
TW (1) TW200526245A (es)
WO (1) WO2005049081A1 (es)
ZA (1) ZA200603065B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CL2008003808A1 (es) * 2007-12-21 2011-03-11 Glaxosmithkline Biologicals Sa Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna.
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776474C (en) 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011092185A1 (en) * 2010-01-28 2011-08-04 Universiteit Gent Salmonella vaccine
CA2842626A1 (en) 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
US20160030443A1 (en) * 2013-03-14 2016-02-04 Rongfu Wang Methods and compositions for modulating regulatory t cell function
RU2717306C2 (ru) 2013-03-15 2020-03-19 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
CN103127098B (zh) * 2013-03-22 2014-05-14 于法周 一种含有克拉维酸或其盐的抗癌药物组合物及制药用途
EP2926815A1 (en) * 2014-04-03 2015-10-07 Institut Curie New derivatives of cephalosporin for treating cancer
CN105616414B (zh) * 2014-10-28 2019-03-05 湘北威尔曼制药股份有限公司 一种氧代哌嗪酰胺类化合物的新用途
CN106999499A (zh) * 2014-10-28 2017-08-01 湘北威尔曼制药股份有限公司 一种氧代哌嗪酰胺类化合物的用途
CN104546863B (zh) * 2015-02-09 2016-09-14 江苏澳格姆生物科技有限公司 头孢噻吩钠在制备抑制肿瘤细胞转移和扩散的药物中的应用
CN107847602A (zh) * 2015-08-06 2018-03-27 日东电工株式会社 免疫诱导促进组合物和疫苗药物组合物
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
CN110302376A (zh) * 2019-04-22 2019-10-08 荆门市动物疫病预防控制中心 一种禽流感疫苗佐剂及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
RU2006117339A (ru) 2007-12-10
IL175373A0 (en) 2006-09-05
AU2004290982B2 (en) 2008-06-19
NO20062918L (no) 2006-08-21
BRPI0416205A (pt) 2006-12-26
AR047728A1 (es) 2006-02-15
CA2546195A1 (en) 2005-06-02
AU2004290982A1 (en) 2005-06-02
RU2322241C2 (ru) 2008-04-20
TW200526245A (en) 2005-08-16
WO2005049081A1 (en) 2005-06-02
JP2007512312A (ja) 2007-05-17
CN1882360A (zh) 2006-12-20
ZA200603065B (en) 2007-08-29
KR100785601B1 (ko) 2007-12-14
KR20060091001A (ko) 2006-08-17
EP1689434A1 (en) 2006-08-16
US20070141086A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
MXPA06005639A (es) Adyuvante antimicrobiano.
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
CR6880A (es) Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis
UA85559C2 (en) Aminobenzophenone compounds
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
SI2380584T1 (sl) Imunostimulatorni postopek
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2005039630A3 (en) Immunogenic compositions
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
WO2009102808A3 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
WO2007003904A3 (en) Prophylactic and immunomodulatory compositions and uses
BR0111785A (pt) Composições e métodos para tratamento de candidìase
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
ATE359815T1 (de) Streptococcus-phocae-vakzine
MY127452A (en) Vaccines.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal